Patient Education and Self-Care for the Management of Jaw Pain upon Awakening: A Randomized Controlled Clinical Trial Comparing the Effectiveness of Adding Pharmacologic Treatment with Cyclobenzaprine or Tizanidine

Aims: To compare the effectiveness of adding cyclobenzaprine, tizanidine, or placebo to patient education and a self-care management program for patients with myofascial pain and specifically presenting with jaw pain upon awakening. Methods: Forty-five patients with a diagnosis of myofascial pain based on the guidelines of the American Academy of Orofacial Pain participated in this 3-week study. The subjects were randomly assigned into one of three groups: placebo group, TZA group (tizanidine 4 mg), or CYC group (cyclobenzaprine 10 mg). Patients were evaluated for changes in pain intensity, frequency, and duration by using the modified Severity Symptoms Index and changes in sleep quality with the use of the Pittsburgh Sleep Quality Index. Data were analyzed by ANOVA and post-hoc or nonparametric statistical tests as appropriate. Results: All three groups had a reduction in pain symptoms and improvement of sleep quality based on a comparison of pretreatment and treatment scores. However, no significant differences among the groups were observed at the posttreatment evaluation. Conclusion: The use of tizanidine or cyclobenzaprine in addition to self-care management and patient education was not more effective than placebo for the management of patients with myofascial jaw pain upon awakening.

cyclobenzaprine; myofascial pain; orofacial pain; sleep; tizanidine

1. Fricton JR, Kroening R, Haley D, Siegert R. Myofascial pain syndrome of the head and neck: A review of clinical characteristics of 164 patients. Oral Surg Oral Med Oral Pathol 1985;60: 615–623.

2. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self­care for the treatment of jaw pain upon awakening: A randomized clinical trial. J Orofac Pain 2002;16:64–70.

3. Wright EF, Schiffman EL. Treatment alternatives for patients with masticatory myofascial pain. J Am Dent Assoc 1995;126: 1030–1039.

4. Leite FM, Atallah AN, El Dib R, et al. Cyclobenzaprine for the treatment of myofascial pain in adults. Cochrane Database Syst Rev 2009;8(3):CD006830.

5. Castro MM, Daltro C. Sleep patterns and symptoms of anxiety and depression in patients with chronic pain. Arq Neuropsiquiatr 2009;67:25–28.

6. Turk DC, Zaki HS, Rudy TE. Effects of intraoral appliance and biofeedback/stress management alone and in combination intreating pain and depression in patients with temporomandibu­lar disorders. J Prosthet Dent 1993;70:158–164.

7. Denucci DJ, Dionne RA, Dubner R. Identifying a neurobiologic basis for drug therapy in TMDs. J Am Dent Assoc 1996; 127:581–593.

8. Dionne RA. Pharmacologic treatments for temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:134–142.

9. Konstantinovic VS, Lazic V. Occlusion splint therapy in patients with craniomandibular disorders (CMD). J Craniofac Surg 2006;17:572–578.

10. Naikmasur V, Bhargava P, Guttal K, Burde K. Soft occlusal splint therapy in the management of myofascial pain dysfunction syndrome: A follow­up study. Indian J Dent Res 2008;19: 196–203.

11. Shen YF, Younger J, Goddard G, Mackey S. Randomized clinical trial of acupuncture for myofascial pain of the jaw muscles.J Orofac Pain 2009;23:353–359.

12. Venancio RA, Alencar Jr FG, Zamperini C. Different substanc­es and dryneedling injections in patients with myofascial pain and headaches. Cranio 2008;26:96–103.

13. Venancio RA, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry­needling injections in patients with myofascial pain and headaches. Cranio 2009;27:46–53.

14. Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: A randomized controlled trial. Clin Rheumatol 2010;29:19–23.

15. Randolph CS, Greene CS, Moretti R, Forbes D, Perry HT. Conservative management of temporomandibular disorders: A posttreatment comparison between patients from a university clinic and from private practice. Am J Orthod Dentofacial Orthop 1990;98:77–82.

16. Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: Review of a decade of clinical experience. Clin Ther 1988;10:216–228.

17. Santandrea S, Montrone F, Sarzi­Puttini P, Boccassini L, Caruso I. A double­blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993;21:74–80.

18. Spiller HA, Winter ML, Mann KV, Borys DJ, Muir S, Krenzelok EP. Five­year multicenter retrospective review of cyclobenzap­rine toxicity. J Emerg Med 1995;13:781–785.

19. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm 1980;37:1313–1323.

20. Basmajian JV. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: Two double­blind controlled clinical and laboratory studies. Arch Phys Med Rehabil 1978;59:58–63.

21. Lance JW, Anthony M. Cyclobenzaprine in the treatment of chronic tension headache. Med J Aust 1972;2:1409–1411.

22. Murros K, Kataja M, Hedman C, et al. Modified­release for­mulation of tizanidine in chronic tension­type headache. Headache 2000;40:633–637.

23. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: A double­blind controlled, multicenter outcome study. Headache 2002;42: 470–482.

24. Pareek A, Chandurkar N, Chandanwale AS, Ambade R, Gupta A, Bartakke G. Aceclofenactizanidine in the treatment of acute low back pain: A double­blind, double­dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009;18:1836–1842.

25. Rapoport AM, Bigal ME. Preventive migraine therapy: What is new. Neurol Sci 2004;25:177–185.

26. Saper JR, Winner PK, Lake AE 3rd. An open­label dose­titra­tion study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 2001;41:357–368.

27. Smith TR. Low­dose tizanidine with nonsteroidal anti­inflammatory drugs for detoxification from analgesic rebound head­ache. Headache 2002;42:175–177.

28. Simons DG, Travell JG, Simons LS. Travell and Simons’s Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol 1 (ed 2). Baltimore: Williams & Wilkins, 1999.

29. De Leeuw R. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management, ed 4. Chicago: Quintessence, 2008.

30. Fricton JR. Musculoskeletal measures of orofacial pain. Anesth Prog 1990;37:136–143.

31. Nixdorf DR, John MT, Wall MM, Fricton JR, Schiffman EL. Psychometric properties of the modified Symptom Severity Index (SSI). J Oral Rehabil. 2010;37:11–20.

32. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28: 193–213.

33. Schiffman EL, Fricton JR, Haley DP, Shapiro BL. The prevalence and treatment needs of subjects with temporomandibular disorders. J Am Dent Assoc 1990;120:295–303.

34. Sanita PV, Alencar FGP Jr. Myofascial Pain Syndrome as a contributing factor in patients with chronic headaches. J Musculosk Pain 2009;17:15–25.

35. Jensen MP, Karoly P. Self­report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R (eds). Handbook of Pain Assessment, ed 2. New York: Guilford Press, 2001:15–34.

36. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.

37. Alencar F Jr, Becker A. Evaluation of different occlusal splints and counselling in the management of myofascial pain dysfunction. J Oral Rehabil 2009;36:79–85.

38. Betucci D, Testa L, Calzoni S, Mantegazza P, Viana M, Monaco F. Combination of tizanidine and amitriptyline in the prophylaxis of chronic tension­type headache: Evaluation of efficacy and impact on quality of life. J Headache Pain 2006;7:34–36.

39. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–121.

40. Malanga GA, Gwynn MW, Smith R, Miller D. Tizanidine is effective in the treatment of myofascial pain syndrome. Pain Physician 2002;5:422–432.

41. Manfredini D, Romagnoli M, Cantini E, Bosco M. Efficacy of tizanidine hydrochloride in the treatment of myofascial face pain. Minerva Med 2004;95:165–171.

42. Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004; 42:593–596.

43. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neu­ropathic pain: An open­label study. J Pain 2000;1:285–292.

44. Merrill RL. Orofacial pain and sleep. Sleep Med Clin 2010;5: 131–144.

45. Chou R, Kim P, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004;28:140–175.

46. Malanga GA, Ruoff GE, Weil AJ, Altman CA, Xie F, Borenstein DG. Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: Two randomized, double­blind, placebo­controlled studies of identical design. Curr Med Res Opin 2009;25:1179–1196.

47. Silberstein S, Tfelt­Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484–495.